On October 16, 2024, Paul Bolno, President and Chief Executive Officer of WAVE Life Sciences Ltd (WVE, Financial), executed a sale of 90,474 shares of the company. The transaction was filed with the SEC and can be viewed in detail through the SEC Filing. Following this transaction, the insider now owns 268,585 shares of WAVE Life Sciences Ltd.
WAVE Life Sciences Ltd is a biotechnology firm focused on delivering transformational therapies for patients with serious, genetically-defined diseases. The company's innovative approach to drug development is aimed at providing treatments that are precisely tailored to the genetics of these diseases.
Over the past year, the insider has sold a total of 138,840 shares and has not made any purchases. The recent sale is part of a broader trend observed over the past year, where WAVE Life Sciences Ltd has seen more insider selling than buying, with 5 insider sells and 4 insider buys.
Shares of WAVE Life Sciences Ltd were trading at $15 on the day of the transaction. The company's market cap is approximately $2.33 billion. According to GF Value, the stock is currently Significantly Overvalued with a price-to-GF-Value ratio of 3.43. The GF Value of $4.37 is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This insider sale might interest investors tracking insider behaviors as an indicator of the company’s future prospects or stock performance. It is essential to consider the broader market conditions and the company's fundamentals before making investment decisions.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
